GE HealthCare’s Q4 Beat Lifts Price Target to $87, AI Fetal Ultrasound Collaboration
Barclays lifted its price target on GE HealthCare to $87 after Q4 2025 results exceeded forecasts and management outlined a 2026 outlook above market estimates. Separately, GE HealthCare launched a collaboration with Diagnoly to embed Fetoly AI fetal screening into its Voluson ultrasound systems, bolstering software-led growth.
1. Barclays Raises Price Target After Q4 Beat
Barclays increased its price target for GE HealthCare to $87 from $86, maintaining an Equal Weight rating, after Q4 2025 revenue and earnings exceeded analysts’ forecasts. The firm highlighted that management’s 2026 guidance surpasses consensus, driven by sustained imaging demand and a robust hospital capital expenditure backlog.
2. Diagnoly Collaboration Embeds AI Into Voluson
GE HealthCare announced a collaboration with Diagnoly to integrate Fetoly, an AI-powered fetal screening tool, into its Voluson women’s health ultrasound systems. Fetoly delivers real-time cardiac and brain analysis during scans, enhancing diagnostic consistency, supporting premium pricing, and expanding GE HealthCare’s software-driven revenue streams.